P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
P38 复发/难治性多发性骨髓瘤 (RRMM) 患者报告结局 (PRO) 接受美洛氟芬和地塞米松 (DEX) 或泊马度胺 (POM) 和 DEX 治疗：来自 3 期 OCEAN 研究的分析
期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1256713
Pesce, Elisa; Cordiglieri, Chiara; Bombaci, Mauro; Eppenberger-Castori, Serenella; Oliveto, Stefania; Manara, Cristina; Crosti, Mariacristina; Ercan, Caner; Coto, Mairene; Gobbini, Andrea; Campagnoli, Susanna; Donnarumma, Tiziano; Martinelli, Manuele; Bevilacqua, Valeria; De Camilli, Elisa; Gruarin, Paola; Sarnicola, Maria L; Cassinotti, Elisa; Baldari, Ludovica; Viale, Giuseppe; Biffo, Stefano; Abrignani, Sergio; Terracciano, Luigi M; Grifantini, Renata; Schjesvold, F; Ludwig, H; Delimpasi, S; Robak, P; Mateos, M; Sandberg, A; Thuresson, M; Norin, S; Richardson, P; Sonneveld, P
